Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death
- 1 March 1999
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (3), 1061
- https://doi.org/10.1200/jco.1999.17.3.1061
Abstract
PURPOSE: To analyze the available data concerning mechanisms of action of and mechanisms of resistance to the antitubulin agents, vinca alkaloids and taxanes, and more recently described compounds. DESIGN: We conducted a review of the literature on classic and recent antitubulin agents, focusing particularly on the relationships between antitubulin agents and their intracellular target, the soluble tubulin/microtubule complex. RESULTS AND CONCLUSION: Although it is widely accepted that antitubulin agents block cell division by inhibition of the mitotic spindle, the mechanism of action of antitubulin agents on microtubules remains to be determined. The classic approach is that vinca alkaloids depolymerize microtubules, thereby increasing the soluble tubulin pool, whereas taxanes stabilize microtubules and increase the microtubular mass. More recent data suggest that both classes of agents have a similar mechanism of action, involving the inhibition of microtubule dynamics. These data suggest that vinca alkaloids and taxanes may act synergistically as antitumor agents and may be administered as combination chemotherapy in the clinic. However, enhanced myeloid and neurologic toxicity, as well as a strong dependence on the sequence of administration, presently exclude these combinations outside the context of clinical trials. Although the multidrug resistance phenotype mediated by Pgp appears to be an important mechanism of resistance to these agents, alterations of microtubule structure resulting in altered microtubule dynamics and/or altered binding of antitubulin agents may constitute a significant mechanism of drug resistance.Keywords
This publication has 81 references indexed in Scilit:
- Method for detection of mutations (M Hasebe et al, JP)Biofutur, 1998
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Journal of Clinical Investigation, 1997
- In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell linesEuropean Journal Of Cancer, 1997
- Microtubule inhibitors differentially affect translational movement, cell surface expression, and endocytosis of transferrin receptors in K562 cellsJournal of Cellular Physiology, 1994
- Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulinProtein Journal, 1994
- Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin a, dolastatins 10 and 15 and halichondrin BPharmacology & Therapeutics, 1992
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- Interaction of reduced glutathione with bovine brain tubulinBiochemical and Biophysical Research Communications, 1985
- A polymer-dependent increase in phosphorylation of beta-tubulin accompanies differentiation of a mouse neuroblastoma cell line.The Journal of cell biology, 1985
- Three expressed sequences within the human β-tubulin multigene family each define a distinct isotypeJournal of Molecular Biology, 1985